News

(Bloomberg) -- Latigo Biotherapeutics Inc., a clinical-stage developer of non-opioid pain medicines, climbed 17% on Friday after raising $345.6 million in an upsized initial public offering, priced at the top of a marketed range.Most Read from BloombergOpenAI’s New Device Will Be Hockey Puck-Sized and Cost Over $300Iran Wants to Bar US, Israeli Ships From Hormuz in Peace AccordIran Says Agreement on Hormuz Shipping Reached With OmanTrump Administration Considers Order on Autism and VaccinesWhy D

(Bloomberg) -- Latigo Biotherapeutics Inc. filed for an initial public offering, joining a growing list of biotechnology firms considering going public as soon as this quarter.Most Read from BloombergFCC Near Rulings Against Disney Over ‘The View,’ TV LicensesChipmakers Bounce After Plunge to Bear-Market Edge: Markets WrapGoogle Gemini Launch Delayed as Tech Falls Short of Internal GoalsChina’s Moonshot Unveils AI Model That Narrows Gap With US FirmsThailand Scraps Plan to End Visa-Free Entry fo